Evidence map›Paper›PMID 32971911›Full record

ArticleMarine drugs2020

Fucoidan from

Xindi Shan, Xueliang Wang, Hao Jiang, Chao Cai, Jiejie Hao, Guangli Yu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Effects of Low-Energy Diets Supplemented withAnimals : an open access journal from MDPI · 2026
    Article
  3. Article
  4. Marine drugs · 2024
    Article
  5. Article
  6. The Combined Metabolically Oriented Effect of Fucoidan from the Brown AlgaInternational journal of molecular sciences · 2023
    Article
  7. Interaction of High-Molecular Weight Fucoidan fromInternational journal of molecular sciences · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xindi ShanKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.ORCID 0000-0003-3951-8766
Xueliang WangKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Hao JiangKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Chao CaiKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.ORCID 0000-0003-4377-3989
Jiejie HaoKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Guangli YuKey Laboratory of Marine Drugs of Ministry of Education, Shandong Provincial Key Laboratory of Glycoscience and Glycotechnology, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.ORCID 0000-0002-6372-9750

Funding

National Major Science and Technology Projects of China 2018ZX09735-004National Natural Science Foundation of China 31670811National Natural Science Foundation of China 81402982National Natural Science Foundation of China 81991522Natural Science Foundation of Shandong Province ZR2017BC007NSFC-Shandong Joint Fund for Marine Science Research Centers U1606403Shandong Provincial Major Science and Technology Innovation Project 2018SDKJ0404
6 · The paper itself

Abstract

We previously demonstrated that fucoidan with a type II structure inhibited postprandial hyperglycemia by suppressing glucose uptake, but the mechanism remains elusive. Here, we aimed to assess whether the effect of glucose absorption inhibition was related to the basic structure of fucoidans and preliminarily clarified the underlying mechanism. Fucoidans with type II structure and type I structure were prepared from

Indexed as

AnimalsAscophyllumBlood GlucoseCaco-2 CellsGlucoseGlucose Tolerance TestHumansHyperglycemiaLaminariaMaleMiceMice, Inbred C57BLPhaeophyceaePolysaccharidesSodium-Glucose Transporter 1Blood GlucosefucoidanGlucosePolysaccharidesSLC5A1 protein, humanSlc5a1 protein, mouseSodium-Glucose Transporter 1fucoidan from Ascophyllum nodosumin vitro and in vivo evaluationpostprandial hyperglycemiaSGLT1

Identifiers

PMID32971911
PMCPMC7551602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.